Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
Date:12/15/2008

(SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the u
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 1% for the Planet , one ... that Kate Williams, the network’s Director of Partnerships, will step ... Williams has been part of 1% for the Planet since ... of the Northern Forest Canoe Trail, a 1% for the ... the stewardship of and advocacy for the outdoors, a commitment ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
(Date:4/20/2015)... New York (PRWEB) April 20, 2015 ... Centers for Medicare & Medicaid Services introduced their new ... HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) ... survey asks patients about their experiences during a recent ... results from July 1, 2013 through June 30, 2014 ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Insuranceautoquote.info has ... find affordable car insurance quotes online . , ... for the best results. Clients should always compare online ... be done on a single website: . http://insuranceautoquote.info ... The questionnaire can be completed in a few minutes ...
Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
... BOSTON, Sept. 15 The 13th Annual ... (HFSA) today featured a discussion titled "Cardiovascular Disease in ... Chen, Director, Stress Echocardiography Program and Program for Cardiac ... Dr. Chen,s presentation highlights the increased risk of heart ...
... , , , ... HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... use of Nexavar((R)) (sorafenib) tablets across tumor types - as ... will be presented at the joint 15th European CanCer Organisation ...
... CRANBURY, N.J., Sept. 15 Palatin Technologies, Inc. ... on clinical trial results with PL-3994, its product for heart ... Meeting of the Heart Failure Society of America in Boston. ... of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive ...
... , , , ... abstract artist Susan Olmetti , one must only step ... step into the company of unconventional characters housed in an outlying charismatic ... mid-1800s and currently inhabited by more than 75 locally owned, independent businesses ...
... ALEXANDRIA, Va., Sept. 15 For overweight men ... cholesterol, high blood pressure, high blood sugar/glucose, poor diet and ... efforts to lose weight, according to Building Healthier America, a ... overweight and obesity in the U.S. , , ...
... , , , CAPE ... experiencing growth across a range of sectors. However, the drive ... medical imaging devices. , , (Logo: ... Frost & Sullivan ( http://www.medicaldevices.frost.com ), Overview ...
Cached Medicine News:Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 2Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 2Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 4Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 5Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 6Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 2Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 3Health News:Wine Reception Mixing up one Part Abstract Artist Susan Olmetti, one Part Chicago House Fundraiser, and one Part SIR Spa 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 3Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 2Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 3
(Date:4/20/2015)... WASHINGTON , April 20, 2015  In ... nation,s healthcare markets, the FTC announced that Cardinal ... it illegally monopolized 25 local markets for the ... hospitals and clinics to pay inflated prices for ... to pay $26.8 million of ill-gotten gains and ...
(Date:4/20/2015)... April 20, 2015  Purdue Pharma, a leading ... Butcher has joined the company as Senior ... will have responsibility for all of Purdue,s efforts ... products that would benefit from our patient-focused commercial ... leader," said Purdue President & CEO Mark ...
(Date:4/20/2015)... YORK , April 20, 2015 ... pump market will continue to be robust; the ... incidence of diabetes, expanding global markets, new product ... there are relatively steady market inhibitors, such as ... an increasing competitive environment. The healthcare market research ...
Breaking Medicine Technology:Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3
... TARRYTOWN, N.Y., Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... the 17th Annual NewsMakers in the Biotech Industry Conference ... for 9:00 a.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
... Oct. 15 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that ... Stock Market indicating that it has regained compliance ... Listed Securities ("MVLS") requirement for continued listing on ...
Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
96-well Silicone Compression Mat, Bulk...
Silicone Compression Mat, Bulk...
96-well Silicone Expansion Mat, Bulk...
Medicine Products: